<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03383276</url>
  </required_header>
  <id_info>
    <org_study_id>2004L00946</org_study_id>
    <nct_id>NCT03383276</nct_id>
  </id_info>
  <brief_title>Phase 1 Study for Safety and Tolerability of IL-1-Ra Topically Administered to Eyes of Healthy Adult Subjects</brief_title>
  <official_title>A Phase 1, Dose Escalating Study of the Safety, Tolerability, and Pharmacokinetics of IL-1-Ra Topically Administered to Eyes of Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tongren Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chengdu Rhodiola Bio-Pharmaceutical Co Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Tongren Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of ocular administration
      of Topical Interleukin-1-Receptor Antagonist in healthy volunteers. Additionally, the PK of
      Interleukin-1-Receptor Antagonist will be assessed.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2017</start_date>
  <completion_date type="Anticipated">June 10, 2018</completion_date>
  <primary_completion_date type="Anticipated">March 25, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Corneal fluorescein staining</measure>
    <time_frame>3 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>3 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular symptomatology</measure>
    <time_frame>3 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Slit lamp examination</measure>
    <time_frame>3 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of intraocularpressure</measure>
    <time_frame>3 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ELISA based assay to determine Pharmacokinetics for the evaluation of systemic exposure of IL-1Ra in healthy volunteers.</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Blepharokeratoconjunctivitis</condition>
  <arm_group>
    <arm_group_label>IL-1Ra</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IL-1Ra</intervention_name>
    <description>custom eye drop to be applied to the left eye.</description>
    <arm_group_label>IL-1Ra</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult males and/or females between the ages of 18 and 45 years

          -  Medically healthy

          -  Best correction vision of greater than or equal to 20/20 in each eye

          -  BMI â‰¥ 19 and &lt; 24 kg/m2

          -  Ability to understand and provide informed consent to participate in this study

          -  Willingness to follow study instructions and likely to complete all required visits

        Exclusion Criteria:

          -  Any ocular or systemic diseases

          -  History of skin or ocular allergy symptoms

          -  Use contact lenses during the trails.

          -  Taking inhaled or oral steroids (for example Advair, Orapred)

          -  Have an active infection

          -  Have serologic evidence of HIV, Hepatitis C, Hepatitis C, or tuberculosis

          -  Receipt of any blood or blood products within 2 months prior to the first dosing day.

          -  Use any drugs within 2 weeks prior to the first dosing day.

          -  Use of cyclosporine, steroid eye drops, serum eye drops, or any other eye medication
             or experimental drug within the past 4 weeks.

          -  Have been exposed to an investigational drug/device within the preceding 3 months

          -  Pregnant or lactating females

          -  History of substance abuse, drug addiction or alcoholism

          -  Males and females unwilling to use an acceptable method of contraception for the
             duration of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiuli Zhao</last_name>
    <phone>0086-010-58268486</phone>
    <email>lilyzhao1028@aliyun.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing TongRen Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feng Wu</last_name>
      <phone>0086-010-58268486</phone>
      <email>trdrug@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2017</study_first_submitted>
  <study_first_submitted_qc>December 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2017</study_first_posted>
  <last_update_submitted>December 22, 2017</last_update_submitted>
  <last_update_submitted_qc>December 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

